Longeveron Inc. (LGVN)

Market Cap	8.40M
Revenue (ttm)	709,000
Net Income (ttm)	-22.21M
Shares Out	4.80M
EPS (ttm)	-10.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	388,251
Open	1.810
Previous Close	1.810
Day's Range	1.730 - 1.880
52-Week Range	1.600 - 44.000
Beta	0.20
Analysts	Strong Buy
Price Target	87.33 (+4,890.29%)
Earnings Date	May 14, 2024

About LGVN

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 12, 2021
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: LGVN

Financial Performance

In 2023, Longeveron's revenue was $709,000, a decrease of -41.98% compared to the previous year's $1.22 million. Losses were -$22.21 million, 17.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for LGVN stock is "Strong Buy." The 12-month stock price forecast is $87.33, which is an increase of 4,890.29% from the latest price.

Price Target

$87.33

(4,890.29% upside)

Analyst Consensus: Strong Buy